Guidelines and Classifications

  • Ronald A. Codario
Part of the Current Clinical Practice book series (CCP)


This autoimmune disease is the result of genetic environmental triggers. These patients demonstrate CD8 cell infiltration of the islet cells that are likely involved with subsequent beta cell destruction. A long prodrome is usually present from genetic pre-disposition to onset of disease. These patients may demonstrate various antibodies to islet antigens including insulin, glutamic acid decarboxylase (GAD), and tyrosine phosphatase 1A-2. Hence, a combination of markers rather than a single test should be used for predictive and diagnostic testing to enhance sensitivity without losing specificity.

Key Words

Type-1 diabetes Insulin dependent diabetes Type-2 diabetes Non-insulin dependent diabetes Screening Diet Medications Gestational diabetes Malnutrition-associated diabetes 


  1. 1.
    Olson DE, Norms SL. Overview3 of AGS guidelines for the treatment of diabetes mellitus in geriatric populations. Geriatrics 2004;59:18–25.PubMedGoogle Scholar
  2. 2.
    Herold KC. Anti-CD3 monoclonal antibody in new onset type-1 diabetes mellitus. N Engl J Med 2002;346:1692.PubMedCrossRefGoogle Scholar
  3. 3.
    Atkinson MA, Eisenbarth GS: Type-1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001;358:221.PubMedCrossRefGoogle Scholar
  4. 4.
    Pietropaolo M, Le Roth D. Pathogenesis of diabetes: our current understanding. Clin Cornerstone 2001;4L:1–16.CrossRefGoogle Scholar
  5. 5.
    Agency for Healthcare Research and Quality. 2007 National Healthcare Disparities Report (NHDR), Agency for Healthcare Research and Quality, Rockville, MD, 2008.Google Scholar
  6. 6.
    Schmidt MI, Duncan BB, Bang H. Identifying individuals at high risk for diabetes. Diabetes Care 2005;28:2013–2018.PubMedCrossRefGoogle Scholar
  7. 7.
    Griffin SJ, Little PS, Hales CN. Diabetes risk score: towards earlier detection of type-2 diabetes in general practice. Diabetes Metab Res Rev 2000;16:164–171.PubMedCrossRefGoogle Scholar
  8. 8.
    Kanaya AM, Wassel Fyr CL, de Rekeneire N. Predicting the development of diabetes in older adults. Diabetes Care 2005;28:404–408.PubMedCrossRefGoogle Scholar
  9. 9.
    Ramlo-Halsted BA, Edelman SV. The natural history of type 2 diabetes. Implications for clinical practice. Prim Care 1999;26:771–789.PubMedCrossRefGoogle Scholar
  10. 10.
    Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population. National Health and Nutrition Examination Survey. 1999–2002. Diabetes Care 2006;29:1263–1268.PubMedCrossRefGoogle Scholar
  11. 11.
    Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106.PubMedCrossRefGoogle Scholar
  12. 12.
    Wellcome Trust Case Control Consortium. Genome wide association study of 14,000 cases of seven common diseases and 3000 shared controls. Nature 2007;447:661–678.CrossRefGoogle Scholar
  13. 13.
    Zeggini E, Scott LJ, Saxena R, Voigt BF, Marchini JL. Meta-analysis of genome wide association data and large scale replication identifies additional susceptibility loci of type-2 diabetes. Nat Genet 2008;40:638–645.PubMedCrossRefGoogle Scholar
  14. 14.
    Engelgau MM, et al. Screening for type 2 diabetes. Diabetes Care 2000;23:1563–1580.PubMedCrossRefGoogle Scholar
  15. 15.
    American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 2003;26(Suppl 1): S21–S24.Google Scholar
  16. 16.
    Rolka DB, Natayan KM, et al. Performance of recommended screening tests for undiagnosed diabetes and dysglycemia. Diabetes Care 2001;24:1899–1903.PubMedCrossRefGoogle Scholar
  17. 17.
    Van Hoeck M, Dehghan A, Witteman JC, van Duijn CM. Predicting type-2 diabetes based on polymorphisms from genome wide association studies: a population based Study. Diabetes 2008;57:3122–3128.CrossRefGoogle Scholar
  18. 18.
    American Diabetes Association. Position Statement: Standards of Medical Care for Patients with Diabetes Mellitus. American Diabetes Association. Diabetes Care 2003;7–27.Google Scholar
  19. 19.
    American Association of Clinical Endocrinologists. Medical guidelines of the management of diabetes mellitus: The AACE system of intensive diabetes self management. 2002 update. Endocr Pract 2002;8(Suppl 1):40–82.Google Scholar
  20. 20.
    Brown AF, Mangione CM, Saliba D, et al. Guidelines for improving the care off the older person with diabetes mellitus. J Am Geriatr Soc 2003;51(5 Suppl Guidelines):S265–S280.PubMedGoogle Scholar
  21. 21.
    Lyssenko V, Jonsson A, Almgren P, Pulizzi N, Isomaa B. Clinical risk factors, DNA variants, and the development of type-2 diabetes. N Engl J Med 2008;359:2220–2232.PubMedCrossRefGoogle Scholar
  22. 22.
    Harris R. Screening adults for type 2 diabetes. Ann Intern Med 2003;138:215.PubMedCrossRefGoogle Scholar
  23. 23.
    Gennuth S. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003;26:3160.CrossRefGoogle Scholar
  24. 24.
    Franz MJ. Evidence based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care 2002;25:148.PubMedCrossRefGoogle Scholar
  25. 25.
    Alberti G. The DAWN study. Pract Diabetes Int 2002;19:22–24.CrossRefGoogle Scholar
  26. 26.
    Codario R, et al. The Vietnam experience, an overview of the health problems associated with Vietnam service. The Pennsylvania Department of Health, Harrisburg, PA, 1989 3–19.Google Scholar
  27. 27.
    Codario R. et al. Toxic Herbicide Exposure, The Physician’s Resource. The Pennsylvania Department of Health, Harrisburg, PA 1984, 2–28.Google Scholar
  28. 28.
    Unwin N, Shaw J, et al. Impaired glucose tolerance and impaired fasting glycemia: the current status on definition and intervention. Diabet Med 2002;19:708–723.PubMedCrossRefGoogle Scholar
  29. 29.
    Gregg EW, Caldwell BL, Cheng YJ, Cowie CC. Trends in the prevalence and ratio of diagnosed to undiagnosed diabetes according to obesity levels in the U.S. Diabetes Care 2004;27:2806–2812.PubMedCrossRefGoogle Scholar
  30. 30.
    Davidson MB. The case for screening for type 2 diabetes in selected populations. BMJ USA 2001;1:297–298.CrossRefGoogle Scholar
  31. 31.
    Selvin E, Marinopaoulos S, Berkenblit G. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Int Med 2004;141:421–431.PubMedCrossRefGoogle Scholar
  32. 32.
    Genuth S, Alberti KG, Bennett P, Puse J, Defronzo R, Kahn R, et al. Follow up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26:3160–3167.PubMedCrossRefGoogle Scholar
  33. 33.
    The European Diabetes Epidemiology group (DECODE). Glucose tolerance and cardiovascular mortality; comparison of fasting and two hour diagnostic criteria. Arch Int Med 2001;161:397–405.CrossRefGoogle Scholar
  34. 34.
    American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004;27(Suppl 1):S15–S35.Google Scholar
  35. 35.
    Kanaya M, Narayan KM. Prevention of type 2 diabetes: data from recent trials. Prim Care 2003; 30:511–526.PubMedCrossRefGoogle Scholar
  36. 36.
    Saaristo T, Peltonen M, Keinanen-Kiukaanniemi S, Vanhala M. National type-2 diabetes prevention programme in Finland. Int J Circumpolar Health. 2007;66:101–112.PubMedGoogle Scholar
  37. 37.
    Pan XR, Li GW, Hu YH, Wang JX, Yang WY. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537–544.PubMedCrossRefGoogle Scholar
  38. 38.
    The DREAM Investigators. The effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose. Lancet 2006;368:1096–1105.CrossRefGoogle Scholar
  39. 39.
    Torgerson JS, Hauptman J, Bodrin MN, Sjostrom. XENical in the prevention of diabetes in obese subjects study. Diabetes Care 2004;27:155–161.PubMedCrossRefGoogle Scholar
  40. 40.
    Mudaliar S, Henry RR. New oral therapies for type-2 diabetes mellitus: the glitazones or insulin sensitizers. Ann Rev Med 2001;52:239–257.PubMedCrossRefGoogle Scholar
  41. 41.
    U.S. Preventive Services Task Force. Screening for type-2 diabetes mellitus in adults: recommendations and rationale. Ann Intern Med 2003;138:212–214.CrossRefGoogle Scholar
  42. 42.
    American Diabetes Association. Standards of care for diabetes mellitus. Diabetes Care 2009;32:1327–1234.CrossRefGoogle Scholar
  43. 43.
    American Diabetes Association. Standards of medical care for patients with diabetes Mellitus. Diabetes Care 2002;25(Suppl 1):S33–S49.Google Scholar

Supplementary Readings

  1. European Diabetes Policy Group 1999. A desktop guide to type 2 diabetes mellitus. Diabet Med 1999; 16(9):716–730.CrossRefGoogle Scholar
  2. Greco P, Eisenberg J. Changing physicians’ practices. New Engl J Med 1993;329(17):1271–1273.PubMedCrossRefGoogle Scholar
  3. Joint National Committee. The sixth report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Arch Intern Med 1997;157(21):2413–2446.CrossRefGoogle Scholar
  4. Lorber D. Revised clinical practice recommendations. Practical Diabetology 2001;3:36–38.Google Scholar
  5. Rao S, et al. Impaired glucose tolerance and impaired fasting glucose. Am Fam Phys 2004;69(8):1961–1968.Google Scholar
  6. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003;26(Suppl 1): S5–S20.Google Scholar
  7. Wagner E, Austin B, Von Korff M. Improving outcomes in chronic illness. Manag Care Q 1996;4(2):12–25.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Ronald A. Codario
    • 1
  1. 1.University of Pennsylvania Health System Thomas Jefferson University HospitalPhiladelphiaUSA

Personalised recommendations